Two Years Audit of Parkinsonism Patients at Royal Commission Hospital Yanbu, Kingdom of Saudi Arabia
Introduction: Parkinson`s disease (PD) is the second most common neurodegenerative condition affecting patients. It is broadly classified as `movement disorder’ with a variety of clinical features, including bradykinesia, rigidity and tremor. PD is better defined as multisystem neurodengerative disorder causing a large number of motor and non-motor complications. In this study we described our experience regarding follow up parkinsonism patients.
Objectives: To determine clinical outcome in patients of Parkinsonism in our setup.
Materials and Methods: This was a retrospective as well as follow up of new patients of Parkinson`s disease in the department of neurology at Royal Commission hospital Yanbu – one of the biggest industrial city of Kingdom of Saudi Arabia. Duration of study was two years; from January 2011 to December 2012. This study included 50 patients with diagnosed case of Parkinsonism and newly diagnosed cases.
Results: The age range was 40 – 110 years; there were 4 patients (8%) of age range 40 – 41 years, 2 patients (4%) of age range 46 – 50 years, one patient (2%), 7 patients (14%) of age range 61 – 65 years, 11 patients (22%) of age range 66 – 70 years, 2 patients (4%) of age range 86 – 90 years and one patient (2%) was of 110 years. The last patient mentioned has a daughter who was 80 years of age and was included in the study. Around 45 patients were diagnosed for the first time as case of Parkinsonism and these were started on management / treatment with good clinical improvement.
Conclusions: Not all the patients need to commence treatment at time of diagnosis, but drugs should be started when symptoms begin to interfere with daily life. We found that all such patients when prescribed treatments sho-wed excellent improvement in terms of activities of daily life.
2. Bradley J. Robottom; William J. Weiner; Lisa M. Shul-man. ―42‖. International Neurology: A Clinical Appr-oach. Blackwell Publishing Ltd. p.152-158.
3. Rao G, Fisch L, Srinivasan S, et al. Does this patient have Parkinson disease? JAMA. 2003; 289 (3): 347-353.
4. Tuite PJ, Krawczewski K. ―Parkinsonism: a review-of-systems approach to diagnosis‖. Seminars in neurology, 2007; 27 (2): 113–22.
5. Christine CW, Aminoff MJ. ―Clinical differentiation of parkinsonian syndromes: prognostic and therapeutic relevance‖. Am. J. Med. 2004; 117 (6): 412–9.
6. Tse W, Cersosimo MG, Gracies JM et al. ―Movement disorders and AIDS: a review‖. Parkinsonism Relat. Disord. 2004; 10 (6): 323–34.
7. Maltête D, Guyant – Maréchal L, Mihout B, Hannequin D. ―Movement disorders and Creutzfeldt – Jakob dise-ase: a review‖. Parkinsonism Relat. Disord. 2006; 12 (2): 65–71.
8. Watanabe Y, Himeda T, Araki T. ―Mechanisms of MP-TP toxicity and their implications for therapy of Parkin-son‘s disease‖ (PDF). Med. Sci. Monit. 2005; 11 (1): RA17–23.
9. Wenning GK, Geser F. ―Multiple system atrophy‖. Rev. Neurol. (Paris) 2003; 159 (5 Pt 2): 3S31–8.
10. Uc EY, Rodnitzky RL. ―Childhood dystonia‖. Seminars in pediatric neurology, 2003; 10 (1): 52–61.
11. Online 'Mendelian Inheritance in Man‘ (OMIM) Neuro-degeneration With Brain Iron Accumulation 1; Nbia1 -234200.
12. DeLong MR, Juncos JL. Parkinson’s Disease and Other Movement Disorders. In: Harrison's Principles of Internal Medicine (16th ed.). McGraw-Hill Profess-ional. 2004: p. 2414.
13. Dinis-Oliveira RJ, Remião F, Carmo H et al. ―Paraquat exposure as an etiological factor of Parkinson's dise-ase‖. Neurotoxicology, 2006; 27 (6): 1110–22.
14. Tremor / Involuntary Movements: Excerpt from Field Guide to Bedside Diagnosis.
15. Weiss J. Chapter 151. Toluene and Xylene. In: Olson KR, ed. Poisoning and Drug Overdose. 6th ed. New York: McGraw-Hill; 2012.
16. Thanvi B, Lo N, Robinson T. ―Vascular Parkinsonism--an important cause of parkinsonism in older people‖ (PDF). Age and ageing, 2005; 34 (2): 114–9.
17. Członkowska A, Tarnacka B, Möller JC et al. ―Unified Wilson‘s Disease Rating Scale — a proposal for the neurological scoring of Wilson‘s disease patients‖. Neurol. Neurochir. 2007; Pol. 41 (1): 1–12.
18. Ropper AH, Samuels MA. Chapter 4. Abnormalities of Movement and Posture Caused by Disease of the Basal Ganglia. In: Ropper AH, Samuels MA, eds. Adams and Victor‘s Principles of Neurology. 9th ed. New York: McGraw-Hill; 2009.
19. Lorincz MT. ―Neurologic Wilson's disease‖. Ann. N. Y. Acad. Sci. January 2010; 1184: 173–87.
Copyright (c) 2018 Pakistan Journal Of Neurological Surgery
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.